| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 05/27/2009 | EP0871487B1 Dendritic cell stimulatory factor |
| 05/27/2009 | CN101443032A Regulation of immune responses by modulation of the function of antigen presenting cells |
| 05/27/2009 | CN101440116A Glycyrrhizin, preparation and use thereof |
| 05/27/2009 | CN101439147A Haiqihuang granules as well as preparation method thereof and pharmacy use |
| 05/27/2009 | CN101439119A External-use medicament for treating urticaria, eczema and skin pruritus |
| 05/27/2009 | CN101439080A Chinese medicinal composition for improving immunity of organism |
| 05/27/2009 | CN101439067A Chinese medicine granular containing ginseng extract and preparation method thereof |
| 05/27/2009 | CN101439059A Ginkgo leaf extract drop and preparation method thereof |
| 05/27/2009 | CN101439056A Technique for preparing Tremella fuciformis spores polysaccharide soft capsules |
| 05/27/2009 | CN101439052A Cicada slough hypersusceptibility-dispelling granular formulation |
| 05/27/2009 | CN101439040A Medical use of 2-O-alpha-L-rhamnose-4,6,4'-trihydroxybenzophenone |
| 05/27/2009 | CN100491389C Sialic combined immunoglobulin like agglutinin inhibitors |
| 05/27/2009 | CN100491374C 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors |
| 05/27/2009 | CN100491368C Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics |
| 05/27/2009 | CN100491355C Cyclic diamine compound having five-membered cyclic group |
| 05/27/2009 | CN100491353C Carboxylic acid derivative capable of inhibiting combination of integrin and its receptor |
| 05/27/2009 | CN100491352C Asymmetrical cyclic diamine compound |
| 05/27/2009 | CN100490915C Otolaryngological delivery device |
| 05/27/2009 | CN100490895C CD40-binding APC-activating molecules |
| 05/27/2009 | CN100490894C Immunotherapic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals |
| 05/27/2009 | CN100490888C Compositions for preventing or treating pollenosis, allergic nephritis, atopic dermatitits, asthma or urticaria |
| 05/27/2009 | CN100490833C Method of supercritical CO2 for extracting terpenoid of effective component of triperygium wilfordii, and composition |
| 05/27/2009 | CN100490811C Piperazine derivative used as CCRS antagonist |
| 05/27/2009 | CN100490809C Tablet comprising cetirizine and pseudoephedrine |
| 05/27/2009 | CN100490804C Ophthalmological use of roflumilast for the treatment of diseases of the eye |
| 05/27/2009 | CN100490791C Compositions and methods to treat neovascularization and disease associated with thereof |
| 05/27/2009 | CN100490676C Health food capable of enhancing immunity and preparation method thereof |
| 05/26/2009 | US7538215 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 05/26/2009 | US7538118 6-aminomorphinane derivatives, method for production and use thereof |
| 05/26/2009 | US7538097 Inhibition of antigen presentation with poorly catabolized polymers |
| 05/26/2009 | US7538089 Anti-inflammatory compounds and uses thereof |
| 05/26/2009 | US7537924 Modified herpes simplex viral particle for targeting and destroying tumor cells |
| 05/26/2009 | US7537887 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 05/26/2009 | US7537763 Tumor necrosis factor specific immunoglobulin for use in treatment and prevention of tumor disorder; tissue targeted therapy |
| 05/26/2009 | US7537756 Using nestin-positive pancreatic stem cell to generate insulin producing beta cells; tissue engineering and repair; regenerative medicine |
| 05/26/2009 | CA2497857C Novel p-selectin ligand protein |
| 05/26/2009 | CA2494165C Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 05/26/2009 | CA2474373C N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substituent on the methyl useful as bradykinin antagonists |
| 05/26/2009 | CA2464223C Quarternary ammonium compounds and their use as antimuscarinic agents |
| 05/26/2009 | CA2463264C 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists |
| 05/26/2009 | CA2459432C Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 05/26/2009 | CA2393072C Mono- and disaccharide derivatives |
| 05/26/2009 | CA2367017C Inhibitors of impdh enzyme |
| 05/26/2009 | CA2295936C Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof |
| 05/26/2009 | CA2254420C Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 05/26/2009 | CA2230492C Human growth hormone variants |
| 05/26/2009 | CA2225903C Aromatic diselenides and selenosulfides, their preparation and their uses, more particularly their therapeutical use |
| 05/26/2009 | CA2216653C 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity |
| 05/22/2009 | WO2009064854A2 Humanized antibodies against tl1a |
| 05/22/2009 | WO2009064155A1 Immunopotentiating composition from labisia pumila extract |
| 05/22/2009 | WO2009064004A1 Citrulline-containing drink |
| 05/22/2009 | WO2009063998A1 Nucleic acid having hydrophobic substance added thereto, and use thereof |
| 05/22/2009 | WO2009063993A1 Fused pyridine derivative and use thereof |
| 05/22/2009 | WO2009063953A1 Phenylpyrazole derivatives |
| 05/22/2009 | WO2009063885A1 Grifola frondosa extract and composition containing the same for promoting the production of hyaluronic acid (hyaluronan) |
| 05/22/2009 | WO2009063215A2 Use of crth2 antagonist compounds |
| 05/22/2009 | WO2009063202A2 Use of crth2 antagonist compounds |
| 05/22/2009 | WO2009062502A1 Method for generating tolerogenic dendritic cells employing decreased temperature |
| 05/22/2009 | WO2009062258A1 N-containing heterocyclic compounds |
| 05/22/2009 | WO2009062238A1 Epitope for neutralizing antibodies |
| 05/22/2009 | WO2009043507A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009043468A3 Use of corticotropin-releasing factor as a therapeutic agent |
| 05/22/2009 | WO2009040087A3 Therapeutic use of peptide yglf and combination with kvlpvpq |
| 05/22/2009 | WO2009040073A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009040032A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009040025A3 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 05/22/2009 | WO2009039969A3 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 05/22/2009 | WO2009033822A3 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent |
| 05/22/2009 | WO2009033812A3 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| 05/22/2009 | WO2009033800A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009033771A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009033736A3 Use of met-enkephalin as a therapeutic agent |
| 05/22/2009 | WO2009033735A3 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
| 05/22/2009 | WO2009033669A3 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent |
| 05/22/2009 | WO2008138968A3 Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg |
| 05/22/2009 | WO2008034032A3 Beta-lactam cannabinoid receptor modulators |
| 05/22/2009 | CA2706556A1 Citrulline-containing beverage |
| 05/22/2009 | CA2705502A1 Phenylpyrazole derivatives |
| 05/22/2009 | CA2705292A1 Humanized antibodies against tl1a |
| 05/22/2009 | CA2703600A1 N-containing heterocyclic compounds |
| 05/21/2009 | US20090131512 Inhibition of type I in IFN production |
| 05/21/2009 | US20090131497 Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments |
| 05/21/2009 | US20090131472 P38 Kinase Inhibiting Agents |
| 05/21/2009 | US20090131470 Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| 05/21/2009 | US20090131461 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity |
| 05/21/2009 | US20090131458 Compounds |
| 05/21/2009 | US20090131456 Caspase inhibitors and uses thereof |
| 05/21/2009 | US20090131438 Triazole derivative |
| 05/21/2009 | US20090131432 type II diabetes mellitus and obesity; dipeptidylpeptidase-IV (DPP-IV) inhibitor; 1-[2-(2-formylaminophenyl)-2-oxoethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine (xanthine=3,7-dihydro-purine-2,6-dione) |
| 05/21/2009 | US20090131429 Pharmaceutical compounds |
| 05/21/2009 | US20090131428 Benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors |
| 05/21/2009 | US20090131421 Compounds for proteasome enzyme inhibition |
| 05/21/2009 | US20090131420 Novel Heterocyclic Analogs of Biphenyl Ethers |
| 05/21/2009 | US20090131379 Vitamin d receptor activators and methods of making |
| 05/21/2009 | US20090131361 Novel Use of MLN51 Gene and Protein |
| 05/21/2009 | US20090131347 Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a th1 phenotype |
| 05/21/2009 | US20090131345 Medicament and method for treating recurrent spontaneous abortion |
| 05/21/2009 | US20090131340 Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations |
| 05/21/2009 | US20090131329 Treatment for allograft rejection |
| 05/21/2009 | US20090130762 Activation of HCV-specific T cells |